Wolfe Research has increased its price target for Gilead Sciences (GILD) to $170 from $155, while maintaining an 'Outperform' rating on the stock. The upward revision reflects growing optimism regarding the company's HIV franchise, which continues to show robust performance and market leadership. Key drivers cited by analysts include the sustained growth of the drug Descovy and the successful market introduction of Yeztugo. The firm projects that Gilead will achieve earnings per share (EPS) of $8.76 by the 2026 fiscal year. This positive outlook persists despite potential headwinds from US policy changes, as the company's core product pipeline remains resilient. The move by Wolfe Research underscores significant confidence in Gilead's long-term profitability and its strategic trajectory within the biotech sector.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis